Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551
This study is recruiting at 20 US sites in 12 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Revolution Medicines, Inc.
- Last updated on ClinicalTrials.gov
- September 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- UC IRVINE Health · Orange, CA
- UC Davis Comprehensive Cancer Center · Sacramento, CA
- Stanford Cancer Institute · Stanford, CA
Colorado · 1
- University of Colorado Cancer Center · Aurora, CO
Florida · 2
- Florida Cancer Specialists · Sarasota, FL
- Moffitt Cancer Center and Research Institute · Tampa, FL
Indiana · 1
- Community Health Network · Indianapolis, IN
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Michigan · 1
- START Midwest · Grand Rapids, MI
New York · 3
- Columbia University · New York, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
- NYU Langone Health · New York, NY
Oklahoma · 1
- University of Oklahoma · Oklahoma City, OK
Pennsylvania · 1
- Allegheny Health Network · Pittsburgh, PA
Tennessee · 1
- Sarah Cannon Research Institue · Nashville, TN
Texas · 4
- MD Anderson · Houston, TX
- NEXT Dallas · Irving, TX
- NEXT Oncology San Antonio · San Antonio, TX
- START Texas · San Antonio, TX
Virginia · 1
- NEXT Oncology Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.